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1 Introduction
Gestational diabetes mellitus (GDM) is the most
common metabolic disorder in pregnancy. The
condition is considered to be associated with
increased perinatal morbidity and mortality [6],
which may be reduced by adequate diagnosis
and management. The diagnosis of GDM is gen-
erally established by means of an oral glucose
tolerance test (OGTT), that is regarded as ab-
normal on the basis of predefined criteria. The
aim of treatment in gestational diabetic patients
is to obtain normoglycemia, which usually re-
quires dietary measures with or without insuline
therapy. In an effort to study the efficacy of the
glucose tolerance test to detect those patients
with GDM who require therapeutic measures to
maintain normoglycemia, we compared the re-
sults of a glucose tolerance test with those of a
glucose profile consisting of three postprandial
glucose values, and with pregnancy outcome.
2 Subjects and methods
During a two-year period, from September 1985
to August 1987, we prospectively studied 250
Caucasian pregnant women considered to be at
risk for GDM. Each woman had one or more
of the following risk factors: a past history of
GDM, a previous macrosomic or hypoglycemic
infant, a positive family history, age 35 years or
more, obesity, recurrent glycosuria, or acceler-
ated fetal growth in the present pregnancy. Pa-
tients with known type 1 or type 2 diabetes
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In all subjects a 50-g OGTT was performed
following three days of glucose loading with at
least 50 g glucose/day and capillary blood was
sampled at 0, 0.5, and 1 hour. On the same day
one of the staff nurses taught the women how
to take their own capillary blood samples at
home. Samples were collected in prelabeled
fluoride oxalate tubes, on the following day one
hour after breakfast, lunch and dinner. Glucose
levels were measured the next day in whole blood
using the hexokinase method (Boehringer Mann-
heim). Only one 50-g OGTT and one home glu-
cose profile (HGP) were obtained from each
subject to be used for comparison. The gesta-
tional age at the time of testing ranged from 16
to 36 weeks, with a median of 29 weeks.
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The OGTT was considered to be abnormal if
one or more of the glucose values exceeded the
upper limits as used in our institution, of 5.3,
9.1 and 8.7 mmol/L at 0, 0.5 and 1.0 hour,
respectively, prior to 28th weeks' gestation, and
of 5.5, 8.4 and 9.2 mmol/L thereafter [4]. The
home glucose profile (HOP) was considered ab-
normal if one or more of the glucose values
exceeded the value of 7.0 mmol/L [4]. A diagnosis
of GDM was rejected when both OGTT and
glucose profile were normal, and no treatment
was instituted. When both the OGTT and the
glucose profile were abnormal, a diagnosis of
GDM was made. These patients were treated
with dietary measures alone or, if necessary to
maintain glucose values at of below 7.0 mmol/L,
in combination with insulin. When one of both
tests was abnormal, the diagnosis of GDM as
well as the necessity for therapeutic measures
was considered to be questionable, and a third
test was performed.
This third test was used as a gold standard, and
consisted of a clinically monitored glucose profile
(CGP). Subjects were on a standard hospital diet
(approximately 40% fat, 45% glucose, 15% pro-
tein, 30 kcal/kg.day) during the test, and capil-
lary whole blood samples were taken one hour
after each of the three main meals. GDM was
considered to be absent and no specific treatment
was given if glucose values did not exceed the
level of 7.0 mmol/L. Patients in whom one or
more glucose concentrations exceeded the value
of 7.0 mmol/L were considered to have gesta-
tional diabetes, and therapeutic measures were
instituted.
Differences in relative frequencies between
groups were tested with the X2-test, and a p value
of < 0.05 was regarded as significant.




























Figure 1. Diagnosis and management of GDM. OGTT
oral glucose tolerancetest HGP home-monitored glu-
cose profile. CGP clinically monitored glucose profile.
3 Results
The glucose test results are shown in figure 1.
Both OGTT and HGP were normal in 197
women and abnormal in 17 women, while in 36
women only one of the two tests was found to
be abnormal. These 36 women were tested again,
using the CDP as a gold standard. Of these 36
women, only 19 had an abnormal CGP and were
treated with diet with or without additional in-
sulin therapy.
Fetal outcome as related to the OGTT and HGP
test results is presented in table I. An abnormal
OGTT was associated with the birth of a large-
for-gestational age infant (weight > 90th centile)
in 6 of 39, or 15% of cases, a normal OGTT
with 21 of 214 large infants (no significant dif-
ference). An abnormal HGP preceded the birth
of a large infant in 7 of 31, or 23% of cases,
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while a normal HGP was associated with 20 of
219, or 9%, large-for-gestational age infants,
again no significant difference. The frequency of
occurrence of instrumental deliveries was similar
between groups. Four perinatal deaths occurred
(1.6%). In three of these cases both OGTT and
HGP had been normal and fetal or neonatal
death appeared to be unrelated to glucose me-
tabolism (one second trimester birth due to cerv-
ical insufficiency, one stillbirth of a severely
growth retarded fetus, one asphyxiated infant
born after placental abruption). In the fourth
case both OGTT and HGP had been abnormal.
Despite treatment with diet and insulin, the in-
fant had a birth weight of 4380 g at 39 weeks
(> P 90). The infant was in good clinical con-
dition and had normal glucose levels during the
first 48 hours after delivery, but died suddenly
on the third day after birth. Postmortem exam-
ination failed to demonstrate the cause of death.
4 Discussion
Patients with GDM tend to deliver large babies,
which may increase the risk of perinatal morbid-
ity [3] and mortality [6]. The most important
risks are: prolonged labor and delivery, hyper-
bilirubinemia, traumatic injury and neonatal hy-
poglycemia [3]. In order to reduce these risks,
considerable effort is put into the detection and
treatment of GDM. However, no agreement ex-
ists about the criteria on which the diagnosis
should be based, about the question how accu-
rate the diagnosis can predict increased risks, or
on the effectiveness of treatment to reduce those
risks [2, 7].
The diagnosis of GDM is usually based on a
abnormal OGTT. However, important differ-
ences exist with regard to patient selection, op-
timum timing, dose and duration of glucose
loading, site and frequency of sampling, method
of glucose assay, and normal ranges [1]. An ab-
normal OGTT does not necessarily mean that
glucose values under less unphysiologic circum-
stances, that is on a normal diet, are abnormal.
In addition, healthy pregnant women at no in-
creased risk of GDM have a 2.3% risk of an
abnormal test if 2 standard deviations above the
mean in uncomplicated pregnancy is used as a
cut-off level. In the present study the OGTT was
abnormal in 39 of 250 women, or 16%, at risk
for GDM. However, 11 of these 39 women (or
28%) with a abnormal OGTT subsequently had
two normal glucose day profiles (HGP and
CGP). Consequently, the OGTT overestimated
the occurrence of hyperglycemia by 28%.
Other investigators screen for GDM by sampling
at one or several occasions during the day, either
at random, or before and after one of the main
meals, or after a glucose load [5]. Again, 2.3%
of healthy pregnant women will have abnormal
test results by statistical definition in many stud-
ies. In the present study, 11 of 219 women, or
5%, with a normal HGP, had both an abnormal
OGTT and an abnormal CGP. This suggests that
the HGP in this study underestimated the oc-
currence of hyperglycemia by 5%.
Even if one assumes that the OGTT overesti-
mates by 28%, and the HGP underestimates by
5% the chance of hyperglycemia, this still leaves
unanswered the question as to what extent mild
to moderate hyperglycemia increases the risks in
the perinatal period, or how effective treatment
of such hyperglycemia is to prevent these risks.
Our study cannot provide the answer to this
question, because all women in whom hypergly-
cemia was identified, were treated. The percent-
ages of large-for-gestational age infants, instru-
mental deliveries, low Apgar scores, and peri-
natal deaths, were slightly, but not significantly,
higher than those in the normoglycemic, un-
treated group. Although this could indicate that
treatment was indeed effective, alternative expla-
nations are that the numbers were too small to
allow valid statistical comparison, or that out-
come would have been just as good without
therapy. Twenty-one large-for-gestational age in-
fants were born from 214 normoglycemic un-
treated mothers. This suggests that one cannot
effectively identify the 10% largest infants in the
population by screening for GDM.
The percentages of instrumental deliveries, low
Apgar scores and perinatal deaths in the nor-
moglycemic women are comparable to those in
the population of pregnant women in our high-
risk obstetric unit; they were apparently not re-
lated to birth weight. This suggests that in
women considered to be at increased risk for
GDM also other risk factors than poor glycemic
control alone may contribute to a fetal outcome
that is less favorable than that in the general
population [6].
Although several authors have argued that treat-
ment of GDM should result in improved out-
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come, the effect of treatment can only be dem-
onstrated in a large randomized study in which
the hyperglycemic controls remain untreated.
Considering the inconvenience, anxiety and costs
of glucose tolerance testing for the patient, a
randomized controlled study of the efficacy of
screening and treatment programs for GDM
may be warranted and ethically justified.
Abstract
In an effort to assess the efficacy of the oral glucose
tolerance test to detect patients with gestational dia-
betes mellitus who require therapeutic measures to
maintain normoglycemia, we compared the results of
an oral glucose tolerance test with those of a home
glucose profile consisting of three postprandial glucose
values in 250 pregnant women.
The OGTT overestimated the occurrence of hypergly-
cemia by 28%, while the home glucose profile under-
estimated the occurrence of hyperglycemia by 5%.
Pregnancy outcome was not significantly different be-
tween spontaneously normoglycemic women and those
who required therapy. One cannot effectively identify
the ten percent largest infants in the population by
screening for gestational diabetes.
Keywords: Diabetes and pregnancy, diabetes screening, gestational diabetes, glucose tolerances test.
der beiden Tests pathologisch aus, wurde die Diagnose
GDM in Zweifel gezogen. In diesen Fällen wurde ein
dritter Test durchgeführt, wobei ein klinisch über-
wachtes Glukoseprofil (CGP) erhoben und als Gold-
Standard benutzt wurde.
Abb. l zeigt die Ergebnisse. Beide Tests waren bei 197
Frauen normal und bei 17 Frauen pathologisch, wäh-
rend bei 36 Frauen lediglich einer der beiden Tests
pathologisch ausfiel. Diese 36 Frauen wurden noch-
mals mit einem CGP als Gold-Standard überprüft, der
bei 19 Frauen pathologisch ausfiel. Hier wurde eine
Diät und, wenn erforderlich, eine Insulintherapie an-
gesetzt. Der OGTT war bei 39 von 250 Frauen mit
Risikofaktoren pathologisch, das entspricht 16%. Je-
doch hatten 11 dieser 39 Frauen (^ 28%) anschließend
zwei normale Blutzuckertagesprofile (HCP und CGP).
Das heißt, daß der OGTT in 28% das Auftreten von
Hyperglykämien überschätzte.
Es gab keinen signifikanten Unterschied bezogen auf
das Schwangerschaftsoutcome zwischen spontan nor-
moglykämischen Frauen und denen, wo eine Therapie
erforderlich war. Ein Screening auf Gestationsdiabetes
ist in der Tat keine effektive Methode, um die 10%
hypertropher Kinder in der Population zu identifizie-
ren.
Oraler Glukose-Toleranztest als Parameter mit geringer
Aussagekraft für eine Hyperglykämie in der Schwan-
gerschaft
Um die Effizienz eines oralen Glukose-Toleranztestes
zur Aufeckung eines Gestationsdiabetes, der therapeu-
tische Maßnahmen zur Einhaltung normoglykämi-
scher Werte erfordert, zu überprüfen, verglichen wir
die Ergebnisse des oralen Glukose-Toleranztestes mit
denen von Blutzuckerprofilen in häuslicher Umge-
bung.
Prospektiv wurden 250 Schwangere mit Risikofakto-
ren für einen Gestationsdiabetes (GDM) untersucht.
Bei allen Patientinnen wurde nach 3 Tagen glukose-
reicher Ernährung ein oraler Glukose-Toleranztest
(50g) mit Blutentnahmen bei 0, 0.5 und l Stunde
durchgeführt. Um ein häusliches Glukoseprofil zu er-
halten, wurde am folgenden Tag jeweils eine Stunde
nach Frühstück, Mittag- und Abendessen Blut abge-
nommen. Von einem pathologischen OGTT gingen wir
aus, wenn die Werte vor der 28. Schwangerschafts-
woche höher als 5.3, 9.1 und 8.7 mmol/1 bei 0, 0.5 und
l Stunde lagen, später wurden die Grenzwerte bei 5.5,
8.4 und 9.2 mmol/1 angesetzt. Das häusliche Glukose-
Profil (HGP) galt als pathologisch, wenn mindestens
einer der Werte 7.0 mmol/1 überstieg. Fiel nur einer
Schlüsselwörter: Diabetes-Screening, Diabetes und Schwangerschaft, Gestationsdiabetes, Glukose-Toleranztest.
Resume
Le test de tolerance au glucose par vote orale est un
mauvais predicateur de l'hyperglycemie au cours de la
Nous avons compare les resultats d'un test de tolerance
au glucose par voie orale avec ceux d'un cycle glyce-
mique a domicile afin d'evaluer Pefficacite du test de
tolerance au glucose par voie orale a depister les pa-
tientes presentant un diabete sucre gestationnel qui
necessitent des mesures therapeutiques pour maintenir
une normoglycemie.
Nous avons etudie 250 femmes enceintes a risque de
diabete gestationnel. Une H. G. P. O. (50 g) a etc realise
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chez tous les sujets apres 3 jours de charge en glucose
et des prelevements sanguins ont etc realises ä 0; 0,5
et 1 heure. Pour le cycle glycemique des prelevements
sanguins ont etc effectues le lendemain une heure apres
le petit dejeuner, le dejeuner et le diner. Les H. G. P. O.
ont ete considerees comme anormales si 1'une ou plus
des valeurs de la glycemie depassaient 5,3; 9,1 et 8,7
mmol/L respectivement ä 0; 0,5 et l heure avant la
28e semaine et 5,5; 8,4 et 9,2 mmol/L apres. Le cycle
glycemique etait considere comme anormal si Tune ou
plusieures glycemies depassaient 7 mmol/L. Lorsqu'un
seul test etait anormal, le diagnostic de diabete gesta-
tionnel etait considere comme sujet ä caution. Dans
ces cas, un troisieme test etait realise ä savoir un cycle
glycemique surveille cliniquement et servait de stan-
dard de reference.
Les resultats des tests sont representes dans la figure
1, chez 197 femmes les deux, H.G.P.O. et cycle gly-
cemique, sont normaux et anormaux chez 17 femmes,
alors que chez 36 femmes, un seul des deux tests est
trouve comme anormal. Ces 36 femmes ont ete etudiees
de nouveau, en prenant le cycle glycemique surveille
cliniquement comme standard de reference. Parmi ces
36 femmes, seules 19 avaient un cycle anormal et ont
ete traitees par le regime avec ou sans insulinotherapie
additionnelle.
L'H. G. P. O. etait anormale chez 39 des 250 femmes,
soit 16%, ä risque de diabete gestationnel. Toutefois,
11 parmi ces 39 femmes (soit 28%) avec H.G P.O.
anormale presentaient ensuite deux cycles glycemiques
normaux. De teile sorte que, PH.G.P.O. surrestime
l'occurence de Fhyperglycemie de 28%.
Uevolution de la grossesse n'est pas signiflcativement
differente entre les femmes spontanement normogly-
cemiques et celles ayant necessite une therapeutique.
En pratique, on ne peut identifier les 10% d'enfants
macrosomes dans la population a Faide de depistage
du diabete gestationnel.
Mots-cles: Depistage du diabete, diabetes et grossesse, diabetes gestationnels, test de tolerance au glucose.
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